Nazy Zomorodian, NP, spoke with CancerNetwork® about the unique dosing schedule of enfortumab vedotin plus pembrolizumab following its accelerated approval by the FDA in advanced/metastatic urothelial cancer.
Nazy Zomorodian, NP
Advertisement
Articles by Nazy Zomorodian, NP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
3
Classifying High-Risk Patients With NDMM
4
Unraveling the Complexities of Proximal-Type Epithelioid Sarcoma of the Vulva
5
